Dimitrios Eleftherios Katsaros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dimitrios Eleftherios Katsaros has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Dimitrios Mougiakakos
Otto von Guericke University Magdeburg
2 shared publications Ahmed Sadek
Department of Paediatric Haematology, Imperial College Healthcare NHS Trust St Mary's Hospital London UK
1 shared publicationAikaterini Theodorou
From the Second Department of Neurology (M.-I.S., L.P., A.T., E.B., D.E.K., G.T.), “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurosciences (Neurology) (D.A.d.S.), Hospital de Santa Maria, University of Lisbon, Portugal; Second Department of Internal Medicine-Propaedeutic and Diabetes Center (P.H.), Medical School, University General Hospital “Attikon,” First Department of Psychiatry (E.T.), Aiginition Hospital, and...
1 shared publicationAnastasia Kotanidou
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
1 shared publicationAndroniki Naska
From the Second Department of Neurology (M.-I.S., L.P., A.T., E.B., D.E.K., G.T.), “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurosciences (Neurology) (D.A.d.S.), Hospital de Santa Maria, University of Lisbon, Portugal; Second Department of Internal Medicine-Propaedeutic and Diabetes Center (P.H.), Medical School, University General Hospital “Attikon,” First Department of Psychiatry (E.T.), Aiginition Hospital, and...
1 shared publication- Barbara J. Bain
Centre for Haematology St Mary's Hospital Campus of Imperial College London Faculty of Medicine London UK
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116925
Evidence for early, clinically silent medial temporal lobe inflammation after CAR-T cell therapy
- 4 July 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116925
Open AccessEvidence for early, clinically silent medial temporal lobe inflammation after CAR-T cell therapy
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
CAR T-cell therapy for neurological disorders: scientific rationale and mechanistic insights
The development and successful clinical application of engineered T cells expressing synthetic chimeric antigen receptors (CARs) represents a milestone in cancer therapy. This approach optimizes physiological in vivo T-cell activation against specific target antigens expressed on defined cell subsets with the goal of their deep and sustained depletion. Significant progress has been made in redesigning CAR T-cell constructs to improve patient safety, therapeutic efficacy, and accessibility. Efforts have also focused on streamlining manufacturing to improve availability and reduce costs, two critical challenges to widespread adoption. Beyond hematologic malignancies, CAR T-cell therapies are now increasingly being repurposed to tackle B-cell-mediated autoimmune diseases (AIDs). This is primarily achieved through broad B-cell depletion, but more targeted approaches—such as the selective elimination of autoantibody-producing B-cell subpopulations—are also being explored. Important considerations in their implementation are identifying the most pertinent patient groups, tailoring their treatment up to the point of CAR-infusion, and following up on their unique toxicity-profile. In the context of neurological AIDs—including refractory myasthenia gravis, Lambert–Eaton syndrome, multiple sclerosis, and stiff-person syndrome—early clinical experience suggests promising efficacy and tolerability, leading to a growing number of registered clinical trials. In this review, we provide an overview of the mechanism and evolution of CAR T-cell therapy, highlighting why its application in AIDs, particularly in neurology, represents a highly promising therapeutic strategy.
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessCAR T-cell therapy for neurological disorders: scientific rationale and mechanistic insights
The development and successful clinical application of engineered T cells expressing synthetic chimeric antigen receptors (CARs) represents a milestone in cancer therapy. This approach optimizes physiological in vivo T-cell activation against specific target antigens expressed on defined cell subsets with the goal of their deep and sustained depletion. Significant progress has been made in redesigning CAR T-cell constructs to improve patient safety, therapeutic efficacy, and accessibility. Efforts have also focused on streamlining manufacturing to improve availability and reduce costs, two critical challenges to widespread adoption. Beyond hematologic malignancies, CAR T-cell therapies are now increasingly being repurposed to tackle B-cell-mediated autoimmune diseases (AIDs). This is primarily achieved through broad B-cell depletion, but more targeted approaches—such as the selective elimination of autoantibody-producing B-cell subpopulations—are also being explored. Important considerations in their implementation are identifying the most pertinent patient groups, tailoring their treatment up to the point of CAR-infusion, and following up on their unique toxicity-profile. In the context of neurological AIDs—including refractory myasthenia gravis, Lambert–Eaton syndrome, multiple sclerosis, and stiff-person syndrome—early clinical experience suggests promising efficacy and tolerability, leading to a growing number of registered clinical trials. In this review, we provide an overview of the mechanism and evolution of CAR T-cell therapy, highlighting why its application in AIDs, particularly in neurology, represents a highly promising therapeutic strategy.
- 2 December 2022
- Published by Wiley in American Journal of Hematology
- Vol. 98 (4) , 690-691
Hemophagocytic lymphohistiocytosis and hemozoin deposition in bone marrow macrophages in falciparum malaria
- 2 December 2022
- Published by Wiley in American Journal of Hematology
- Vol. 98 (4) , 690-691
Hemophagocytic lymphohistiocytosis and hemozoin deposition in bone marrow macrophages in falciparum malaria
- 4 October 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (14) , E1465-E1474
Acute Arterial Ischemic Stroke Following COVID-19 Vaccination
Background: Acute arterial-ischemic-stroke (AIS) has been reported as a rare adverse-event following COVID-19-vaccination with mRNA or viral-vector vaccines. However, data are sparse regarding the risk of post-vaccination AIS and its potential association with thrombotic-thrombocytopenia-syndrome (TTS). Methods: A systematic review and meta-analysis of randomized-controlled clinical trials (RCTs), pharmacovigilance registries, registry-based studies, observational cohorts and case-series was performed with the aim to calculate: (1) the pooled proportion of patients presenting with AIS following COVID-19-vaccination; (2) the prevalence of AIS after mRNA and vector-based vaccination; (3) the proportion of TTS among post-vaccination AIS-cases. Patient characteristics were assessed as secondary outcomes. Results: Two RCTs, three cohort and eleven registry-based studies comprising 17,481 AIS-cases among 782,989,363 COVID-19-vaccinations were included in the meta-analysis. The pooled proportion of AIS following exposure to any COVID-19-vaccine type was 4.7 cases per 100,000 vaccinations (95%CI:2.2-8.1; I2=99.9%). The pooled proportion of AIS following mRNA-vaccination (9.2 cases per 100,000 vaccinations; 95%CI: 2.5-19.3; I2=99.9%) did not differ compared to adenovirus-based-vaccination (2.9 cases per 100,000 vaccinations; 95%CI: 0.3-7.8; I2=99.9%). No differences regarding demographics were disclosed between patients with AIS following mRNA- or vector-based vaccination. The pooled proportion of TTS among post-vaccination AIS-cases was 3.1% (95%CI: 0.7-7.2%; I2=78.8%). Conclusions: The pooled proportion of AIS following COVID-19 vaccination is comparable to the prevalence of AIS in the general population and much lower than the AIS prevalence among SARS-CoV-2-infected patients. TTS is very uncommonly reported in patients with AIS following COVID-19 vaccination.
- 4 October 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (14) , E1465-E1474
Acute Arterial Ischemic Stroke Following COVID-19 Vaccination
Background: Acute arterial-ischemic-stroke (AIS) has been reported as a rare adverse-event following COVID-19-vaccination with mRNA or viral-vector vaccines. However, data are sparse regarding the risk of post-vaccination AIS and its potential association with thrombotic-thrombocytopenia-syndrome (TTS). Methods: A systematic review and meta-analysis of randomized-controlled clinical trials (RCTs), pharmacovigilance registries, registry-based studies, observational cohorts and case-series was performed with the aim to calculate: (1) the pooled proportion of patients presenting with AIS following COVID-19-vaccination; (2) the prevalence of AIS after mRNA and vector-based vaccination; (3) the proportion of TTS among post-vaccination AIS-cases. Patient characteristics were assessed as secondary outcomes. Results: Two RCTs, three cohort and eleven registry-based studies comprising 17,481 AIS-cases among 782,989,363 COVID-19-vaccinations were included in the meta-analysis. The pooled proportion of AIS following exposure to any COVID-19-vaccine type was 4.7 cases per 100,000 vaccinations (95%CI:2.2-8.1; I2=99.9%). The pooled proportion of AIS following mRNA-vaccination (9.2 cases per 100,000 vaccinations; 95%CI: 2.5-19.3; I2=99.9%) did not differ compared to adenovirus-based-vaccination (2.9 cases per 100,000 vaccinations; 95%CI: 0.3-7.8; I2=99.9%). No differences regarding demographics were disclosed between patients with AIS following mRNA- or vector-based vaccination. The pooled proportion of TTS among post-vaccination AIS-cases was 3.1% (95%CI: 0.7-7.2%; I2=78.8%). Conclusions: The pooled proportion of AIS following COVID-19 vaccination is comparable to the prevalence of AIS in the general population and much lower than the AIS prevalence among SARS-CoV-2-infected patients. TTS is very uncommonly reported in patients with AIS following COVID-19 vaccination.
- 3 October 2022
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 16 (10) , 1101-1108
Mortality of intubated patients with COVID-19 during first and subsequent waves: a meta-analysis involving 363,660 patients from 43 countries
We attempted to investigate the change in mortality of intubated patients with coronavirus disease (COVID-19) from first to subsequent waves across several countries.We pre-registered our meta-anal...
- 3 October 2022
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 16 (10) , 1101-1108
Mortality of intubated patients with COVID-19 during first and subsequent waves: a meta-analysis involving 363,660 patients from 43 countries
We attempted to investigate the change in mortality of intubated patients with coronavirus disease (COVID-19) from first to subsequent waves across several countries.We pre-registered our meta-anal...